366 Diagnostic Challenges and Treatment Barriers in the Management of Diffuse Intrinsic Pontine Glioma (DIPG) in Low- and Lower-Middle-Income Countries (LMICs)

View at publisher Summarise with VIRAT
Authors: Salaar Ahmed, Hania Fatima, Haseeb Waheed, Muhammad Abdullah, Shariqa Batool, Naureen Mushtaq
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric brainstem tumor with a poor prognosis. In low- and middle-income countries (LMICs), challenges to diagnosis and treatment are exacerbated by limited resources and health system constraints. METHODS: A systematic review was conducted according to PRISMA 2020 guidelines. Searches were performed across PubMed/MEDLINE, Scopus, and Cochrane Library for studies up to December 2024. Two independent reviewers screened 2,034 records. Data analysis and descriptive statistics were conducted using R version 4.2.2. RESULTS: Sixteen studies from six LMICs were included, covering 1,527 DIPG cases—mostly from South Asia (n = 8) and North Africa (n = 5). Median diagnostic delays ranged from 1–6 months, often due to inefficient referral systems. While neuroimaging was reported to be available in most (14) studies, biopsy was inaccessible in 11 out of 16 studies included; where done, diagnostic yield ranged from 8.3% to 39.1%. Molecular testing was reported in only five centers. Radiotherapy access was limited in six studies and inconsistently utilized elsewhere. Palliative care and multidisciplinary involvement were documented in just 18.7% and 37.5% of centers, respectively. Presenting symptoms included cranial nerve palsies (45.8–88%), headache (51.4–77.8%), and ataxia (48–77.8%). Median survival ranged from 6.0 to 9.7 months, with follow-up abandonment rates as high as 71.4%. CONCLUSIONS: DIPG care in LMICs is hindered by significant diagnostic and treatment barriers, including delayed presentation, limited access to biopsy and molecular testing, and inadequate palliative and multidisciplinary support. These findings highlight the urgent need for improved infrastructure, referral systems, and access to comprehensive neuro-oncology care.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Advances in Oncology and Radiotherapy Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
99–99
Publication date
26 March 2026
Language
EN